Background
• Therapies for rare diseases have ignited industry-wide debates concerning patient access, pricing and efficacy. Urea cycle disorders (UCD), a genetic rare disease, is a target for enzyme replacement therapies, yet UCD epidemiology data are scarce. For payers and pharmaceutical companies to accurately forecast patient cost of care, accurate patient population estimates are a necessity.
Objectives
• The objective of this study is to estimate the prevalence of UCD in the 0-17 year-old population in five major European markets (EU5) (France, Germany, Italy, Spain, UK).
Methods
• We included males and females ages 0-17 years. We excluded patients older than 17 years to remove the mild patients, who may not require therapy, and have a population that better represents severe patients requiring chronic, expensive treatment.
• We designed an incidence-survival model utilizing birth incidence, annual lifeexpectancy and country-specific newborn data. Birth incidence estimates for UCD were obtained from the Urea Cycle Disorders Consortium (UCDC).
• We conducted a literature review to determine the annual life expectancy of UCD.
• Finally, we reviewed available EU5 newborn census data to obtain the number of newborns in each country from 2001 to 2012. We extrapolated the trend from 2001-2012 to forecast the number of newborns through 2024. These data were entered into the incidence-survival model to calculate the prevalence of UCD from 2015-2024.
Results
• We estimated a prevalence of 1.71 per 100,000 population in the 0-17 year age groups resulting in 1,027 and 1,033 UCD cases in the EU5 in 2015 and 2024, respectively.
• The prevalence was 1.89 per 100,000 in the 0-4 year-old age group, 1.63 per 100,000 in the 10-14 year-old age group, and 1.57 per 100,000 in 15-17 yearold age group.
• The survival of UCD decreased considerably over the first 10 years of life, from a 73% survival at age 1 year to a 58% survival at age 10 years.
• The five most frequent subtypes of UCD (OTCD, ASLD, ASSD, ARGD) constitute collectively 93.1% of the UCD population. The proportions are 59.9%, 15.5%, 14.2%, 3.5%, respectively.
Conclusions
• To our knowledge, this study provides the first prevalence estimate of UCD in the EU5 markets.
• Incidence-survival models provide an alternative method to estimating prevalent cases when prevalence data are scarce or unreliable.
• With 1,027 estimated cases in 2015, it is expected that UCD treatments will be expensive given the small size of the patient population.
• With low expected survival, treatment options should target the 0-10 years pediatric age group.
• In conclusion, these estimates can be used to approximate the total cost burden of UCD and the resulting cost-effectiveness of UCD treatments. 
